NASDAQ OMX

TrueCommerce Announces Acumatica Integration

Dela

New solution offers global commerce connectivity and connected fulfilment capabilities for the world's fastest-growing cloud ERP

PITTSBURGH, Pa., June 27, 2018 (GLOBE NEWSWIRE) -- TrueCommerce, a global provider of trading partner connectivity and integration solutions, today announced its integration with Acumatica, the world's fastest-growing cloud ERP. The new TrueCommerce offering helps organizations maximize ROI with this popular business system by integrating both wholesale trading partners and digital commerce channels while also automating order-to-cash interactions and fulfillment processes - all in an easy-to-use and maintain, hosted environment.

"TrueCommerce works with leading ERP providers to extend their native platforms by integrating commerce and fulfillment interactions across their user's respective value chains," said TrueCommerce president Ross Elliott. "Acumatica is a fast-growing ERP provider serving a large community of dynamic organizations. We decided to make a strategic investment to offer them the full breadth of TrueCommerce capabilities that includes our best-in-class unified commerce suite."

TrueCommerce for Acumatica features and benefits include:

  • Through a single connection with Acumatica, TrueCommerce provides immediate integration with a global connected trading partner community, including support for XML and global EDI data standards
  • Fully integrates business documents exchanged with customers including sales orders, order confirmations and invoice transactions
  • Powerful business rules automatically validate unit pricing, purchase order numbers, items and more before processing transactions into Acumatica
  • Multi-channel integration including pre-built connectors for dropship vendor programs, fast-growing online marketplaces and e-commerce storefront systems
  • Accelerates drop-ship, marketplace and e-commerce orders processing by automatically creating new customers within Acumatica when a new sales order is created
  • Simplifies fulfillment through direct integration with 3rd party logistics (3PL) partners or utilization of TrueCommerce's fully integrated Pack & Ship application
  • The TrueCommerce Packing List and compliance labeling add-ons simplifies the management of all trading partner requirements for packing list templates, including content, data and graphics             

"Our diverse customer community knows that Acumatica partners with best-in-class organizations to maximize ROI in our platform," says Christian Lindberg, Vice President of Partner Solutions for Acumatica. "TrueCommerce offers a vast pre-connected commerce network, ease of deployment and reliability. We see great promise in TrueCommerce's abilities to help our customers compete in today's digital first multi-channel environment, and we are looking forward to working together."

TrueCommerce's Acumatica integration is an extension of TrueCommerce Foundry - a broad set of unified commerce services and apps that connects customers, suppliers, channels, and systems. This platform revolutionizes supply chain visibility and collaboration by helping organizations make the most of their omni-channel initiatives through business P2P connectivity, order management, collaborative replenishment, intelligent fulfillment, cross-functional analytics, and product information management.

The solution leverages TrueCommerce's Global Commerce Network that includes over 92,000 pre-connected retailers, distributors and logistics service providers. A true managed services provider, TrueCommerce manages the onboarding process for new trading partners as well as the ongoing management of trading partner specific mapping and labeling changes.

For more information, visit: TrueCommerce Acumatica Integration

About Acumatica
Acumatica provides cloud-based business management software that enables small and mid-size companies to accelerate their businesses. Built on cloud and mobile technology and a unique customer-centric licensing model, Acumatica delivers a suite of fully integrated business management applications, such as Financials, Project Accounting, Distribution, Commerce, Manufacturing, Field Service and CRM, on a robust and flexible platform. For more information, visit www.acumatica.com.

About TrueCommerce
TrueCommerce revolutionizes trading partner connectivity, visibility, and collaboration by linking suppliers, retail hubs and end consumers in one global commerce network. 

With our flexible, integrated and fully managed service solutions, customers of any size can easily connect and collaborate with any trading partner while enjoying the peace of mind of a proven service platform that reliably handles hundreds of millions of transactions annually without the need for any customer interaction.

From the factory to the warehouse, from distributor to retail storefront, achieve new levels of business connectivity and performance with the world's most complete commerce network. 

TrueCommerce: Connect. Integrate. Accelerate.

For more information, visit https://www.truecommerce.com.

Media Contact
Yegor Kuznetsov, TrueCommerce
703-209-0167
yegor.kuznetsov@truecommerce.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TrueCommerce via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Bergman & Beving AB: Share-based incentive scheme25.9.2018 10:00Pressmeddelande

Press Release Share-based incentive scheme The share-based incentive scheme resolved by the 2018 Annual General Meeting where 16 members of senior management were offered to acquire up to 210,000 call options on repurchased class B shares has been fully subscribed. The call options will be transferred at a price of SEK 7.10 per call option, equivalent to the market value according to an external independent valuation, applying the Black-Scholes-model. The redemption price of the call options amounts to SEK 117.90, equivalent to 120 percent of the volume-weighted average of the paid market price for the shares during the period from 24 August to 7 September 2018, inclusive. Each call option entitles the holder to acquire one repurchased class B share during the period from 13 September 2021 to 10 June 2022, inclusive. Stockholm den 25 September 2018 Bergman & Beving AB (publ) Contact information Peter Schön, CFO, Bergman & Beving AB, Tel: +46 70 339 89 99 The information was submitted f

Bergman & Beving AB: Aktierelaterat incitamentsprogram25.9.2018 10:00Pressmeddelande

Pressrelease Aktierelaterat incitamentsprogram Det av årsstämman 2018 beslutade aktierelaterade incitamentsprogrammet som omfattar 16 ledningspersoner om maximalt 210 000 köpoptioner på återköpta aktier av serie B har fulltecknats. Köpoptionerna kommer att överlåtas till ett pris av 7,10 SEK per köpoption vilket motsvarar marknadsvärde enligt en extern oberoende värdering utförd i enlighet med Black-Scholes-modellen. Lösenkursen för köpoptionerna uppgår till 117,90 SEK motsvarande 120 procent av den genomsnittliga aktiekursen under mätperioden 24 augusti - 7 september 2018. Varje köpoption berättigar till förvärv av en återköpt aktie av serie B under perioden från och med den 13 september 2021 till och med den 10 juni 2022. Stockholm den 25 september 2018 Bergman & Beving AB (publ) För ytterligare information kontakta: Peter Schön, CFO, telefon 070-339 89 99 Informationen lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 25 september 2018 kl. 10:00 CET. Ber

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board17.9.2018 08:00Pressmeddelande

Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine at Roswell Park Comprehensive Cancer Center, and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical Cancer Research programme, Faculty of Health Sciences, University of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT), and consultant in Oncology, Herlev University Hospital. Both Scientific Advisory Board members will serve as a strategic resource to Immunicum as the company continues to advance the clinical development of its lead product, ilixadencel. "We are honored to have such highly specialized experts in the field of immuno-oncology and cell therapy join our Scientific Advisory Board a

Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet17.9.2018 08:00Pressmeddelande

Pressmeddelande 17 september 2018 Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet Immunicum AB (publ; IMMU.ST) meddelade i dag att två ledande immun-onkologiska experter har valts in i bolagets vetenskapliga råd för att fungera som strategiska resurser för Immunicum under bolagets fortsatta kliniska utveckling av sin ledande produkt, ilixadencel. Pawel Kalinski, MD, PhD, vice ordförande för translationell forskning vid den medicinska institutionen vid Roswell Park Comprehensive Cancer Center, och Inge Marie Svane, MD, PhD, professor, chef för det kliniska cancerforskningsprogrammet på medicinska fakulteten vid Köpenhamns universitet, chef för Center för cancerimmunterapi (CCIT) samt överläkare inom onkologi, Herlevs universitetssjukhus har valts in i rådet. - Vi är hedrade att ha experter med specialistkompetens inom området immunonkologi och cellterapi i vårt vetenskapliga råd, vilka kan erbjuda ytterligare vägledning när det

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum